trending Market Intelligence /marketintelligence/en/news-insights/trending/9HpfKJwaqwaPOwhcpTV7eQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA proposes warning label for breast implant products

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA proposes warning label for breast implant products

The U.S. Food and Drug Administration has proposed that manufacturers put warning labels on breast implant products to better inform patients of the risks associated with their use.

Risks stated on the boxed warning label should include that implants are not considered lifetime medical devices, risk of complication increases over time, and that breast implants have been associated with breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL, according to the guidance. Along with the labeling recommendations, the agency also proposed that a checklist outlining risks associated with breast implants be provided to patients.

If finalized, the guidance will not be legally binding on manufacturers, according to the agency. The draft was released Oct. 23 and will be in a public comment period through Dec. 23.

Certain breast implant products have been connected to BIA-ALCL, a form of the immune system cancer non-Hodgkin's lymphoma. The cancer tends to be located in scar tissue and fluid around the implant but can spread across the entire body, according to the FDA.

"An individual's risk of developing [anaplastic large cell lymphoma] is considered to be low; however, this cancer is serious and can lead to death, especially if not treated promptly," the agency said in its Oct. 23 draft guidance.

The FDA was cautious about connecting a separate health risk that it called "breast implant illness" to use of certain products in the draft guidance, saying the "exact relationship of these symptoms with breast implants is unclear at this time."

Breast implant illness refers to a set of symptoms reported to the agency that include fatigue, memory loss, rash and joint pain.

The FDA updated safety information on July 24 that showed the agency has received 573 reported cases of BIA-ALCL, including 33 patient deaths. Of the total reports, 481 were reported to have been patients who had Allergan PLC products. The FDA recommended at the time that Allergan pull certain breast implant products from the market. The company issued a worldwide recall of all Biocell breast implants and tissue expanders in response.

Health Canada banned the Allergan products from being sold in the country May 28. Allergan pulled the products from the European market in December 2018 after its regulatory approval expired.